How has Bruker's trading securities in marketable securities changed year-over-year?

Bruker's trading securities in marketable securities decreased by 24.3% year-over-year, from $34.2M to $25.9M.

Bruker BRKR Trading Securities in Marketable Securities

Trading Securities in Marketable Securities at other companies

Agilent TechnologiesA

——

IlluminaILMN

——

Bio-Rad LaboratoriesBIO

——

Other financials

Income statement

See full

Revenue$823.4M+2.7%

Gross profit$379.8M-2.9%

Operating income$10.2M-67.9%

Net income$14.4M-17.2%

EPS (diluted)$0.02-81.8%

Balance sheet

See full

Cash & equivalents$137.6M-26.7%

Total debt$1.7B-20.9%

Total equity$2.5B+34.6%

Total assets$6.1B+3.3%

Cash flow

See full

Operating cash flow$71.2M+9.5%

CapEx$24.2M-6.9%

Free cash flow$47.0M+20.5%

Valuation

See full

Market cap$8.71B-13.2%

Enterprise value$10.25B-14.9%

P/S2.5×-0.4×

Profitability

See full

Gross margin45.3%-3.7pp

Operating margin1.3%-5.0pp

Net margin-0.6%-10.0pp

FCF margin1.5%-3.6pp

Returns & leverage

See full

Return on equity-1%-21.2pp

Debt / equity0.7×-0.5×

Current ratio1.6×0.0×

Where this comes from

Reported directly by Bruker in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.

The official record: Bruker’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bruker's trading securities in marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bruker's trading securities in marketable securities?: Bruker (BRKR) reported trading securities in marketable securities of $25.9M in Q1 2026.
How has Bruker's trading securities in marketable securities changed year-over-year?: Bruker's trading securities in marketable securities decreased by 24.3% year-over-year, from $34.2M to $25.9M.